<DOC>
	<DOCNO>NCT01506661</DOCNO>
	<brief_summary>Herpes Zoster ( shingle ) cause reactivation latent varicella zoster virus ( VZV ) usually occur decade follow initial exposure . The risk develop shingle increase age . Shingles present painful , itchy blister rash usually involve single portion skin last 7-10 day . The risk develop shingle increase age healthy people , show study increase people rheumatoid arthritis autoimmune disease . Zostavax , live-attenuated vaccine varicella zoster virus , first approve FDA prevention Shingles among people 60 year old , approve use people age 50 year old . Because rheumatoid arthritis medication use treat rheumatoid arthritis impair body 's immune system , know much immune response generate people rheumatoid arthritis . The goal study measure immune response standard vaccination Zostavax people rheumatoid arthritis comparison people healthy immune system . All participant 50 year old old , subject rheumatoid arthritis eligible take certain biologic medication , include TNF inhibitor ( Etanercept Adalimumab ) . Ten healthy subject 10 subject rheumatoid arthritis receive single vaccination Zostavax , follow 12 week assess immune response development local rash potential side effect .</brief_summary>
	<brief_title>Zostavax Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥ 50 year Willing able provide write informed consent History primary varicella vaccination positive VZV IgG antibodies Diagnosis RA accord ACR criterion &gt; 1 year , healthy control subject Stable , mild disease activity define DAS28 score 4.0 Current medical treatment RA stable 4 week prior screen Acceptable immunosuppressive medication limit Prednisone ≤ 10 mg daily Methotrexate ≤ 20 mg weekly Hydroxychloroquine ≤ 6.5 mg/kg daily Any TNF inhibitor Female subject childbearing potential nonsterile male must agree use acceptable form contraception duration study History receive VZVcontaining vaccine History herpes zoster reactivation ( shingle ) within 5 year enrollment Received vaccine within 6 week Known Hepatitis B , C HIV virus infection History drug alcohol abuse within 1 year Rituximab therapy within 2 year screen Cyclophosphamide within 6 month screen Biologic therapy : TNF inhibitor longer halflives ( infliximab , golimumab , etc ) , nonTNF biologic therapy ( IL1 IL6 inhibition , CTLA4Ig ) Use mycophenolate mofetil within 3 month screen History receive immunoglobulin blood product within 3 month screen Allergic reaction , intolerance contraindication use famciclovir . Has receive experimental/investigational agent ( vaccine , drug , biologic , device , blood product , medication ) within 3 month screen ; expect receive another experimental/investigational agent within 6 month post immunization . Pregnant lactate woman Unwilling use acceptable method contraception duration study WBC &lt; 3.0 ; ANC &lt; 1500 ; CD4+ &lt; 200 Proteinuria &gt; 1.5 mg/day Impaired renal function define serum Cr &gt; 1.5 Transaminases &gt; 2x upper limit normal DAS28 &gt; 4 Anticipation need increase level immunosuppression add biologic therapy 6 month follow dosing . History neoplastic disease within 5 year screen , except completely excise nonmelanoma cancer skin insitu carcinoma uterine cervix . History hematological malignancy , current bleeding disorder take anticoagulant medication ( heparin warfarin ) . Any condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>vaccination</keyword>
	<keyword>immune response</keyword>
	<keyword>varicella zoster</keyword>
</DOC>